



= 750-kDa accessory proteins¹

150-kDa core neurotoxin¹

You and your patients can have confidence in BOTOX[®] Cosmetic (onabotulinumtoxinA)

TRUST IN THE TIME-TESTED FORMULATION FROM ALLERGAN



IMPORTANT SAFETY INFORMATION, INCLUDING BOXED WARNING

WARNING: DISTANT SPREAD OF TOXIN EFFECT

Postmarketing reports indicate that the effects of BOTOX[®] Cosmetic and all botulinum toxin products may spread from the area of injection to produce symptoms consistent with botulinum toxin effects. These may include asthenia, generalized muscle weakness, diplopia, ptosis, dysphagia, dysphonia, dysarthria, urinary incontinence, and breathing difficulties. These symptoms have been reported hours to weeks after injection. Swallowing and breathing difficulties can be life threatening and there have been reports of death. The risk of symptoms is probably greatest in children treated for spasticity, but symptoms can also occur in adults treated for spasticity and other conditions, particularly in those patients who have an underlying condition that would predispose them to these symptoms. In unapproved uses and approved indications, cases of spread of effect have been reported at doses comparable to those used to treat cervical dystonia and spasticity and at lower doses.

Please see Indications and additional Important Safety Information on following pages.
For more information on BOTOX[®] Cosmetic, please see accompanying full Prescribing Information including Boxed Warning and Medication Guide.

BOTOX[®]
COSMETIC
onabotulinumtoxinA
injection

THERE'S ONLY ONE BOTOX[®] COSMETIC

BOTOX[®]
COSMETIC
onabotulinumtoxinA
injection

THERE'S ONLY ONE BOTOX[®] COSMETIC


BOTOX[®]
COSMETIC
onabotulinumtoxinA
injection

THERE'S ONLY ONE BOTOX[®] COSMETIC

ALL BOTULINUM TOXINS ARE UNIQUE

Botulinum toxins, like BOTOX[®] Cosmetic, are *biologics*—
inherently unique, derived from living organisms, and
sensitive to manufacturing differences^{2,3}

Large, structurally complex
molecules cannot be
easily replicated, unlike
conventional, chemically
synthesized drugs^{2,3}



BOTOX[®] Cosmetic (onabotulinumtoxinA) Important Information

Indications

BOTOX[®] Cosmetic (onabotulinumtoxinA) is indicated in adult patients for the temporary improvement in the appearance of:

- Moderate to severe glabellar lines associated with corrugator and/or procerus muscle activity
- Moderate to severe lateral canthal lines associated with orbicularis oculi activity
- Moderate to severe forehead lines associated with frontalis activity

IMPORTANT SAFETY INFORMATION (continued)

CONTRAINDICATIONS

BOTOX[®] Cosmetic is contraindicated in the presence of infection at the proposed injection site(s) and in individuals with known hypersensitivity to any botulinum toxin preparation or to any of the components in the formulation.

WARNINGS AND PRECAUTIONS

Lack of Interchangeability Between Botulinum Toxin Products

The potency units of BOTOX[®] Cosmetic are specific to the preparation and assay method utilized. They are not interchangeable with other preparations of botulinum toxin products and, therefore, units of biological activity of BOTOX[®] Cosmetic cannot be compared to nor converted into units of any other botulinum toxin products assessed with any other specific assay method.

Please see additional Important Safety Information on following pages.

DIFFERENCES IN BOTULINUM TOXINS RESULT IN NONINTERCHANGEABILITY

BOTOX[®] Cosmetic: The product is the process

Molecular size

BOTOX[®] Cosmetic is a large, uniform
≈ 900-kDa complex molecule
(core neurotoxin and
accessory proteins).¹

Manufacturing process

The BOTOX[®] Cosmetic manufacturing
process affects the clinical characteristics
of the product, including formulation,
dosage, and administration.⁴

Formulation

Each 50-Unit or 100-Unit
BOTOX[®] Cosmetic vial contains
Clostridium botulinum type A neurotoxin
complex, human serum albumin,
and sodium chloride.⁵

Potency assay and units

BOTOX[®] Cosmetic uses a proprietary
cell-based potency assay specific to its
formulation. This assay determines
units of biological activity.⁵

BOTOX[®] Cosmetic (onabotulinumtoxinA) IMPORTANT SAFETY INFORMATION (continued)

WARNINGS AND PRECAUTIONS (continued)

Spread of Toxin Effect

Please refer to Boxed Warning for Distant Spread of Toxin Effect.

No definitive serious adverse event reports of distant spread of toxin effect associated with dermatologic use of BOTOX[®] Cosmetic at the labeled dose of 20 Units (for glabellar lines), 24 Units (for lateral canthal lines), 40 Units (for forehead lines with glabellar lines), 44 Units (for simultaneous treatment of lateral canthal lines and glabellar lines), and 64 Units (for simultaneous treatment of lateral canthal lines, glabellar lines, and forehead lines) have been reported. Patients or caregivers should be advised to seek immediate medical care if swallowing, speech, or respiratory disorders occur.

Serious Adverse Reactions With Unapproved Use

Serious adverse reactions, including excessive weakness, dysphagia, and aspiration pneumonia, with some adverse reactions associated with fatal outcomes, have been reported in patients who received BOTOX[®] injections for unapproved uses. In these cases, the adverse reactions were not necessarily related to distant spread of toxin, but may have resulted from the administration of BOTOX[®] to the site of injection and/or adjacent structures. In several of the cases, patients had pre-existing dysphagia or other significant disabilities. There is insufficient information to identify factors associated with an increased risk for adverse reactions associated with the unapproved uses of BOTOX[®]. The safety and effectiveness of BOTOX[®] for unapproved uses have not been established.

Please see additional Important Safety Information on following pages.


AT APPROVED DOSES, BOTULINUM TOXINS PERFORM DIFFERENTLY⁶

Botulinum toxins are NOT interchangeable⁵

- “The potency Units of BOTOX[®] Cosmetic are specific to the preparation and assay method utilized. They are not interchangeable with other preparations of botulinum toxin products and, therefore, units of biological activity of BOTOX[®] Cosmetic cannot be compared to nor converted into units of any other botulinum toxin products assessed with any other specific assay method”⁵

Duration From a Double-Blind, Randomized, Parallel-Group Study for Moderate to Severe Glabellar Lines⁶

Incidence of at least 1-grade improvement from baseline in glabellar line severity at maximum contraction



■ BOTOX[®] Cosmetic (20 Units) (n = 31) ■ Dysport[®] (abobotulinumtoxinA) (50 Units) (n = 31)

Adverse events

- Three BOTOX[®] Cosmetic and 2 Dysport[®] patients experienced bruising⁶
- One BOTOX[®] Cosmetic patient experienced a temporary forehead lump⁶

BOTOX[®] Cosmetic (onabotulinumtoxinA) IMPORTANT SAFETY INFORMATION (continued)

WARNINGS AND PRECAUTIONS (continued)

Hypersensitivity Reactions

Serious and/or immediate hypersensitivity reactions have been reported. These reactions include anaphylaxis, serum sickness, urticaria, soft-tissue edema, and dyspnea. If such reactions occur, further injection of BOTOX[®] Cosmetic should be discontinued and appropriate medical therapy immediately instituted. One fatal case of anaphylaxis has been reported in which lidocaine was used as the diluent and, consequently, the causal agent cannot be reliably determined.

Cardiovascular System

There have been reports following administration of BOTOX[®] of adverse events involving the cardiovascular system, including arrhythmia and myocardial infarction, some with fatal outcomes. Some of these patients had risk factors including pre-existing cardiovascular disease. Use caution when administering to patients with pre-existing cardiovascular disease.

Increased Risk of Clinically Significant Effects With Pre-existing Neuromuscular Disorders

Individuals with peripheral motor neuropathic diseases, amyotrophic lateral sclerosis, or neuromuscular junction disorders (eg, myasthenia gravis or Lambert-Eaton syndrome) should be monitored when given botulinum toxin. Patients with neuromuscular disorders may be at increased risk of clinically significant effects including generalized muscle weakness, diplopia, ptosis, dysphonia, dysarthria, severe dysphagia, and respiratory compromise from onabotulinumtoxinA (see *Warnings and Precautions*).

Please see additional Important Safety Information on following page.

BOTOX® Cosmetic (onabotulinumtoxinA) IMPORTANT SAFETY INFORMATION (continued)

WARNINGS AND PRECAUTIONS (continued)

Dysphagia and Breathing Difficulties

Treatment with BOTOX® and other botulinum toxin products can result in swallowing or breathing difficulties. Patients with pre-existing swallowing or breathing difficulties may be more susceptible to these complications. In most cases, this is a consequence of weakening of muscles in the area of injection that are involved in breathing or oropharyngeal muscles that control swallowing or breathing (see *Boxed Warning*).

Pre-existing Conditions at the Injection Site

Caution should be used when BOTOX® Cosmetic treatment is used in the presence of inflammation at the proposed injection site(s) or when excessive weakness or atrophy is present in the target muscle(s).

Dry Eye in Patients Treated With BOTOX® Cosmetic

There have been reports of dry eye associated with BOTOX® Cosmetic injection in or near the orbicularis oculi muscle. If symptoms of dry eye (eg, eye irritation, photophobia, or visual changes) persist, consider referring patients to an ophthalmologist.

Human Albumin and Transmission of Viral Diseases

This product contains albumin, a derivative of human blood. Based on effective donor screening and product manufacturing processes, it carries an extremely remote risk for transmission of viral diseases and variant Creutzfeldt-Jakob disease (vCJD). There is a theoretical risk for transmission of Creutzfeldt-Jakob disease (CJD), but if that risk actually exists, the risk of transmission would also be considered extremely remote. No cases of transmission of viral diseases, CJD or vCJD have ever been identified for licensed albumin or albumin contained in other licensed products.

ADVERSE REACTIONS

The most frequently reported adverse reactions following injection of BOTOX® Cosmetic for glabellar lines were eyelid ptosis (3%), facial pain (1%), facial paresis (1%), and muscular weakness (1%).

The most frequently reported adverse reaction following injection of BOTOX® Cosmetic for lateral canthal lines was eyelid edema (1%).

The most frequently reported adverse reactions following injection of BOTOX® Cosmetic for forehead lines with glabellar lines were headache (9%), brow ptosis (2%), and eyelid ptosis (2%).

DRUG INTERACTIONS

Co-administration of BOTOX® Cosmetic and aminoglycosides or other agents interfering with neuromuscular transmission (eg, curare-like compounds) should only be performed with caution as the effect of the toxin may be potentiated. Use of anticholinergic drugs after administration of BOTOX® Cosmetic may potentiate systemic anticholinergic effects.

The effect of administering different botulinum neurotoxin products at the same time or within several months of each other is unknown. Excessive neuromuscular weakness may be exacerbated by administration of another botulinum toxin prior to the resolution of the effects of a previously administered botulinum toxin.

Excessive weakness may also be exaggerated by administration of a muscle relaxant before or after administration of BOTOX® Cosmetic.

USE IN SPECIFIC POPULATIONS

There are no studies or adequate data from postmarketing surveillance on the developmental risk associated with use of BOTOX® Cosmetic in pregnant women. There are no data on the presence of BOTOX® Cosmetic in human or animal milk, the effects on the breastfed child, or the effects on milk production.

**For more information on
BOTOX® Cosmetic, please see
accompanying full Prescribing
Information including Boxed Warning
and Medication Guide.**

REFERENCES: 1. Lietzow MA, Gielow ET, Le D, Zhang J, Verhagen MF. Subunit stoichiometry of the *Clostridium botulinum* type A neurotoxin complex determined using denaturing capillary electrophoresis. *Protein J*. 2008;27(7-8):420-425. 2. US Food and Drug Administration. Frequently asked questions about therapeutic biological products. US Food and Drug Administration website. <http://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/TherapeuticBiologicApplications/ucm113522.htm>. Updated July 7, 2015. Accessed August 7, 2020. 3. Roger SD, Mikhail A. Biosimilars: opportunity or cause for concern? *J Pharm Pharm Sci*. 2007;10(3):405-410. 4. Brin MF, James C, Maltman J. Botulinum toxin type A products are not interchangeable: a review of the evidence. *Biologics*. 2014;8:227-241. 5. BOTOX® Cosmetic Prescribing Information, July 2020. 6. Lowe P, Patnaik R, Lowe N. Comparison of two formulations of botulinum toxin type A for the treatment of glabellar lines: a double-blind, randomized study. *J Am Acad Dermatol*. 2006;55(6):975-980.



© 2020 Allergan. All rights reserved. All trademarks are the property of their respective owners.
hcp.BotocCosmetic.com 1-800-BOTOXMD Re-order: BCT101610-v4 08/20 007326

